论文部分内容阅读
目的:探讨DNA甲基转移酶DNMT1与EZH2在急性髓系白血病(AML)中的表达及其相关性。方法:采用荧光定量PCR技术检测50例AML患者和30例正常供者骨髓细胞中DNMT1与EZH2mRNA的表达水平,分析DNMT1表达水平与临床特征和预后的关系及其与EZH2的相关性。结果:AML患者骨髓细胞中DNMT1mRNA的表达显著高于正常供者[(2.72±0.73)∶(0.89±0.27),P<0.01];EZH2mRNA的表达水平也显著高于正常供者[(4.39±1.06)∶(1.87±0.33),P<0.01];EZH2与DNMT1的表达水平呈显著正相关(r=0.51,P=0.002);DNMT1mRNA表达水平与外周血幼稚细胞比例≥60%、WBC≥50×109/L显著相关(均P<0.05);DNMT1mRNA高表达组患者中位生存时间15个月(95%CI9~19个月),显著低于DNMT1mRNA低表达组患者的32个月(95%CI27~40个月)(P=0.006)。结论:DNMT1和EZH2在AML患者中均高表达,二者表达水平呈正相关,DNMT1与AML患者预后不良相关。
Objective: To investigate the expression of DNA methyltransferase DNMT1 and EZH2 in acute myeloid leukemia (AML) and their correlation. Methods: The expression of DNMT1 and EZH2 mRNA in 50 AML patients and 30 normal donors were detected by real-time fluorescence quantitative PCR. The relationship between DNMT1 expression and clinical features and prognosis and EZH2 was analyzed. Results: The expression of DNMT1 mRNA in AML patients was significantly higher than that in normal donors [(2.72 ± 0.73) vs (0.89 ± 0.27), P <0.01]. EZH2 mRNA expression was also significantly higher than that in normal donors [(4.39 ± 1.06 ) (1.87 ± 0.33), P <0.01]. There was a significant positive correlation between EZH2 and DNMT1 expression (r = 0.51, P = 0.002) .The ratio of DNMT1 mRNA expression to peripheral blood mononuclear cells was 60% 109 / L (all P <0.05). The median survival time of patients with DNMT1 mRNA overexpression was 15 months (95% CI 9-19 months), significantly lower than that of DNMT1 low expression patients 32 months (95% CI 27 ~ 40 months) (P = 0.006). Conclusion: Both DNMT1 and EZH2 are highly expressed in AML patients. The expression of DNMT1 and EZH2 are positively correlated with each other. DNMT1 is associated with poor prognosis in AML patients.